{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:57:52Z","timestamp":1793051872525,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004769","name":"Universit\u00e0 degli Studi di Pavia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40256-025-00778-1","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T12:31:56Z","timestamp":1766233916000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6216-7741","authenticated-orcid":false,"given":"Luca","family":"Raone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Gritti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Mandurino-Mirizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Maria","family":"Sparasci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Scotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Currao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Colonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ferlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"issue":"8","key":"778_CR1","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","volume":"151","author":"SS Martin","year":"2025","unstructured":"Martin SS, Aday AW, Allen NB, et al. 2025 Heart disease and stroke statistics: a report of us and global data from the American Heart Association. Circulation. 2025;151(8):e41\u2013660. https:\/\/doi.org\/10.1161\/CIR.0000000000001303.","journal-title":"Circulation"},{"issue":"8","key":"778_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1714\/4531.45338","volume":"26","author":"FM Sparasci","year":"2025","unstructured":"Sparasci FM, Raone L, Currao A, et al. Livelli di trigliceridi nei pazienti in prevenzione secondaria nel mondo reale: approfondimenti dal registro JET-LDL [Real-world triglyceride levels in secondary prevention: insights from the JET-LDL registry]. G Ital Cardiol (Rome). 2025;26(8):613\u20138. https:\/\/doi.org\/10.1714\/4531.45338.","journal-title":"G Ital Cardiol (Rome)."},{"issue":"5","key":"778_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jacl.2017.06.015","volume":"11","author":"ND Wong","year":"2017","unstructured":"Wong ND, Zhao Y, Quek RGW, et al. Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis. J Clin Lipidol. 2017;11(5):1223\u201333. https:\/\/doi.org\/10.1016\/j.jacl.2017.06.015.","journal-title":"J Clin Lipidol"},{"issue":"Suppl N","key":"778_CR4","doi-asserted-by":"publisher","first-page":"N132","DOI":"10.1093\/eurheartj\/suaa207","volume":"22","author":"M Casula","year":"2020","unstructured":"Casula M, Taietti I, Zeqaj I, et al. 386 Achieving LDL cholesterol target in a real-world secondary prevention cohort: when two is better than one. Eur Heart J. 2020;22(Suppl N):N132\u20134. https:\/\/doi.org\/10.1093\/eurheartj\/suaa207.","journal-title":"Eur Heart J"},{"key":"778_CR5","doi-asserted-by":"publisher","unstructured":"Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis [published correction appears in N Engl J Med. 2011 Nov 24;365(21):2040]. N Engl J Med. 2011;364(3):226\u2013235. https:\/\/doi.org\/10.1056\/NEJMoa1002358.","DOI":"10.1056\/NEJMoa1002358"},{"issue":"2","key":"778_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_59_19","volume":"20","author":"R Hajar","year":"2019","unstructured":"Hajar R. PCSK 9 inhibitors: a short history and a new era of lipid-lowering therapy. Heart Views. 2019;20(2):74\u20135. https:\/\/doi.org\/10.4103\/HEARTVIEWS.HEARTVIEWS_59_19.","journal-title":"Heart Views"},{"issue":"22","key":"778_CR7","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"18","key":"778_CR8","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"16","key":"778_CR9","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"7","key":"778_CR10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","volume":"15","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging. 2022;15(7):1308\u201321. https:\/\/doi.org\/10.1016\/j.jcmg.2022.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"18","key":"778_CR11","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. JAMA. 2022;327(18):1771\u201381. https:\/\/doi.org\/10.1001\/jama.2022.5218.","journal-title":"JAMA"},{"issue":"22","key":"778_CR12","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384. https:\/\/doi.org\/10.1001\/jama.2016.16951.","journal-title":"JAMA"},{"issue":"20","key":"778_CR13","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.010.","journal-title":"J Am Coll Cardiol"},{"key":"778_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.amjcard.2024.09.022","volume":"233","author":"AR Munaf\u00f2","year":"2024","unstructured":"Munaf\u00f2 AR, Ferlini M, Varbella F, et al. Low-density lipoprotein cholesterol goal achievement and self-reported medication adherence: insights from the JET-LDL registry. Am J Cardiol. 2024;233:55\u201361. https:\/\/doi.org\/10.1016\/j.amjcard.2024.09.022.","journal-title":"Am J Cardiol"},{"key":"778_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131659","volume":"397","author":"M Ferlini","year":"2024","unstructured":"Ferlini M, Munaf\u00f2 A, Varbella F, et al. Achievement of target LDL-cholesterol level in patients with acute coronary syndrome undergoing percutaneous coronary intervention: The JET-LDL registry. Int J Cardiol. 2024;397:131659. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131659.","journal-title":"Int J Cardiol"},{"issue":"1","key":"778_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01542-4","volume":"21","author":"X Wang","year":"2022","unstructured":"Wang X, Wen D, Chen Y, Ma L, You C. PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a Bayesian network meta-analysis. Cardiovasc Diabetol. 2022;21(1):107. https:\/\/doi.org\/10.1186\/s12933-022-01542-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"778_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"issue":"1","key":"778_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-021-01528-3","volume":"20","author":"F Gao","year":"2021","unstructured":"Gao F, Wang ZJ, Ma XT, Shen H, Yang LX, Zhou YJ. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography. Lipids Health Dis. 2021;20(1):106. https:\/\/doi.org\/10.1186\/s12944-021-01528-3.","journal-title":"Lipids Health Dis"},{"issue":"18","key":"778_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025551","volume":"11","author":"PP Toth","year":"2022","unstructured":"Toth PP, Bray S, Villa G, et al. Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol. J Am Heart Assoc. 2022;11(18):e025551. https:\/\/doi.org\/10.1161\/JAHA.122.025551.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"778_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.pathol.2018.10.012","volume":"51","author":"V Blanchard","year":"2019","unstructured":"Blanchard V, Khantalin I, Ramin-Mangata S, Ch\u00e9mello K, Nativel B, Lambert G. PCSK9: from biology to clinical applications. Pathology. 2019;51(2):177\u201383. https:\/\/doi.org\/10.1016\/j.pathol.2018.10.012.","journal-title":"Pathology"},{"issue":"6","key":"778_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2022.100507","volume":"1","author":"M Shariff","year":"2022","unstructured":"Shariff M, Kumar A, Kansara T, et al. Network meta-analysis of trials comparing intravascular ultrasound, optical coherence tomography, and angiography-guided technique for drug-eluting stent implantation. J Soc Cardiovasc Angiogr Interv. 2022;1(6):100507. https:\/\/doi.org\/10.1016\/j.jscai.2022.100507.","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"23","key":"778_CR22","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.jacc.2023.09.823","volume":"82","author":"T Kuno","year":"2023","unstructured":"Kuno T, Kiyohara Y, Maehara A, et al. Comparison of intravascular imaging, functional, or angiographically guided coronary intervention. J Am Coll Cardiol. 2023;82(23):2167\u201376. https:\/\/doi.org\/10.1016\/j.jacc.2023.09.823.","journal-title":"J Am Coll Cardiol"},{"key":"778_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132936","volume":"422","author":"A Mandurino-Mirizzi","year":"2025","unstructured":"Mandurino-Mirizzi A, Munaf\u00f2 AR, Rizzo F, et al. Comparison of different guidance strategies to percutaneous coronary intervention: a network meta-analysis of randomized clinical trials. Int J Cardiol. 2025;422:132936. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132936.","journal-title":"Int J Cardiol"},{"key":"778_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133290","volume":"433","author":"F Colivicchi","year":"2025","unstructured":"Colivicchi F, Fabbri G, Oliva F, et al. LDL-cholesterol levels and lipid lowering therapy in secondary prevention. Baseline data from the BRING-UP prospective registry. Int J Cardiol. 2025;433:133290. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133290.","journal-title":"Int J Cardiol"},{"issue":"4","key":"778_CR25","doi-asserted-by":"publisher","DOI":"10.5837\/bjc.2023.044","volume":"30","author":"P Devaiah","year":"2023","unstructured":"Devaiah P, Handjiev S, George J. Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice. Br J Cardiol. 2023;30(4):44. https:\/\/doi.org\/10.5837\/bjc.2023.044.","journal-title":"Br J Cardiol"},{"issue":"15","key":"778_CR26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061620.","journal-title":"Circulation"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00778-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00778-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:23:56Z","timestamp":1771507436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00778-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00778-1","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luca Raone, Valeria Gritti, Alessandro Mandurino-Mirizzi, Francesco Maria Sparasci, Valeria Scotti, Alessia Currao, Giuseppe Colonna, Marco Ferlini, and Leonardo De Luca declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Conceptualization:\u00a0Valeria Gritti, Marco Ferlini, Luca Raone. Methodology:\u00a0Luca Raone, Francesco Maria Sparasci, Valeria Scotti, Valeria Gritti, Alessandro Mandurino Mirizzi. Data curation and analysis:\u00a0Luca Raone, Francesco Maria Sparasci, Valeria Scotti. Software and statistical analysis:\u00a0Alessandro Mandurino Mirizzi. Investigation:\u00a0Luca Raone, Francesco Maria Sparasci, Valeria Gritti. Supervision:\u00a0Marco Ferlini, Leonardo De Luca, Valeria Gritti, Alessandro Mandurino Mirizzi, Giuseppe Colonna. Writing\u2014original draft:\u00a0Luca Raone, Francesco Maria Sparasci. Writing\u2014review and editing:\u00a0All authors. Project administration:\u00a0Luca Raone","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}